Literature DB >> 29387193

TASK-1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial-mesenchymal transition in lung cancer.

Xing-Guang Wang1, Na-Xin Yuan2, Xin-Peng Li2, Fang-Fang Chen3.   

Abstract

Cancer initiating cell (CIC) formation and epithelial-mesenchymal transition (EMT) are pivotal events in lung cancer cell invasion and metastasis. They have been shown to occur in gefitinib resistance. Studying the molecular mechanisms of CICs, EMT and acquired gefitinib resistance will enhance the understanding of the pathogenesis and progression of the disease and offer novel targets for effective therapies. TWIK-related acid-sensitive K(+) (TASK-1) is expressed in a subset of non-small-cell lung cancer (NSCLC) cell lines, where it promotes cell proliferation while inhibiting apoptosis. In the present study, TASK-1 was demonstrated to induce gefitinib resistance in the A549 NSCLC cell line. Overexpression of TASK-1 promoted the acquisition of CIC-like traits by A549 cells. CD133, octamer-binding transcription factor 4 (OCT-4) and Nanog have been suggested to be markers of CICs in lung cancer. It was demonstrated that overexpression of TASK-1 promoted CD133, OCT-4 and Nanog protein expression in A549 cells. Increased formation of stem cell-like populations results in EMT of cancer cells. The present study found that overexpression of TASK-1 promoted EMT of A549 cells. Thus, downregulation of TASK-1 may represent a novel strategy for EMT reversal, decreasing CIC-like traits and increasing gefitinib sensitivity of NSCLCs.

Entities:  

Keywords:  TASK-1; cancer initiating cells; epithelial-mesenchymal transition; lung cancer

Year:  2017        PMID: 29387193      PMCID: PMC5768110          DOI: 10.3892/etm.2017.5426

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  42 in total

Review 1.  Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.

Authors:  Stefan Grünert; Martin Jechlinger; Hartmut Beug
Journal:  Nat Rev Mol Cell Biol       Date:  2003-08       Impact factor: 94.444

2.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

Review 3.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

4.  Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.

Authors:  Shih-Hwa Chiou; Mong-Lien Wang; Yu-Ting Chou; Chi-Jen Chen; Chun-Fu Hong; Wang-Ju Hsieh; Hsin-Tzu Chang; Ying-Shan Chen; Tzu-Wei Lin; Han-Sui Hsu; Cheng-Wen Wu
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Authors:  Feng Jiang; Qi Qiu; Abha Khanna; Nevins W Todd; Janaki Deepak; Lingxiao Xing; Huijun Wang; Zhenqiu Liu; Yun Su; Sanford A Stass; Ruth L Katz
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

Review 6.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

7.  Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.

Authors:  Jin Kyung Rho; Yun Jung Choi; Jin Kyung Lee; Baek-Yeol Ryoo; Im Il Na; Sung Hyun Yang; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  Lung Cancer       Date:  2008-07-02       Impact factor: 5.705

8.  Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

Authors:  Daniel B Costa; Susumu Kobayashi; Daniel G Tenen; Mark S Huberman
Journal:  Lung Cancer       Date:  2007-07-03       Impact factor: 5.705

9.  Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.

Authors:  Janet Wangari-Talbot; Elizabeth Hopper-Borge
Journal:  J Can Res Updates       Date:  2013-10-31

Review 10.  Lung cancer stem cells.

Authors:  Sharon R Pine; Blair Marshall; Lyuba Varticovski
Journal:  Dis Markers       Date:  2008       Impact factor: 3.434

View more
  2 in total

Review 1.  Ion Channels in Lung Cancer.

Authors:  Etmar Bulk; Luca Matteo Todesca; Albrecht Schwab
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  Potassium Channels as a Target for Cancer Therapy: Current Perspectives.

Authors:  Leandro Zúñiga; Angel Cayo; Wendy González; Cristian Vilos; Rafael Zúñiga
Journal:  Onco Targets Ther       Date:  2022-07-20       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.